Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity

Posted on by

Distributed through LillyDirect®’s self-pay channel, Zepbound single-dose vials are at least 50% less than the list price of all other incretin medicines for obesity INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced Zepbound® (tirzepatide) 2.5…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.